Phuturdex › Diseases › Musculoskeletal disorder
Drugs in development · updated 30 October 2026
Musculoskeletal disorder: drugs in development
As of 30 October 2026 there are 23 active clinical trials (recruiting or ongoing, phases I–III) on 22 drugs for musculoskeletal disorder. 10 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Andecaliximab | II–III | 1 | NCT06508021 |
| AOC 1044 | III | 1 | NCT07587242 |
| BMN 333 | II–III | 1 | NCT07441876 |
| Encaleret | III | 1 | NCT05680818 |
| VX-670 | I–II | 2 | NCT06185764 |
| KK8123 | I–II | 1 | NCT06525636 |
| AZD5492 | I | 1 | NCT06916806 |
| BMS-986515 | I | 1 | NCT07115745 |
| Hyaluronic Acid | Early I | 1 | NCT07434115 |
| Nanofat | Early I | 1 | NCT07434115 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| VosoritideBMN 111, Voxzogo® | II–III | 5 | NCT07441876 |
| InfigratinibTruseltiq®, Febseltiq® | II–III | 4 | NCT06873035 |
| AdalimumabHadlima, Simlandi® | III | 1 | NCT02629159 |
| Autologous cultured chondrocytes on porcine collagen membrane | III | 1 | NCT06915233 |
| FinasteridePropecia®, Proscar® | II–III | 1 | NCT07742553 |
| OrforglipronFoundayo® | III | 1 | NCT07153471 |
| Testosterone cypionateAzmiro® | II–III | 1 | NCT07742553 |
| Triamcinolone Acetonidezilretta, Kenalog { | II–III | 1 | NCT07151417 |
| UpadacitinibRinvoq Lq®, Rinvoq® | III | 1 | NCT02629159 |
| CyclophosphamideCyclophosphamid, Cytoxan | I | 1 | NCT07115745 |
| FludarabineFludara, FLUDARABIN | I | 1 | NCT07115745 |
| TocilizumabTociluzumab, Avtozma | I | 1 | NCT07115745 |
Sorted by most advanced phase and number of active trials.
All 22 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Rheumatoid arthritis 130 drugs
- Duchenne muscular dystrophy 35 drugs
- Systemic lupus erythematosus 178 drugs
- Knee osteoarthritis 37 drugs
- Myositis 42 drugs
- Psoriatic arthritis 48 drugs
- Systemic scleroderma 77 drugs
- Sjogren's Syndrome 29 drugs
- Autoimmune disease 94 drugs
- Dermatomyositis 52 drugs
- Arthritis, Juvenile 39 drugs
- Osteoarthritis 20 drugs
Broader categories
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Skin and connective tissue diseases 3 drugs
- Endocrine system disease 19 drugs
- Nutritional and metabolic diseases 5 drugs
- Connective tissue disease 21 drugs
- Metabolism, Inborn Errors 6 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009140 “Musculoskeletal Diseases”.